证券代码：688553 证券简称：汇宇制药 公告编号：2025-093 四川汇宇制药股份有限公司 持股 5%以上股东股份被轮候冻结的公告 近日，公司股东黄乾益先生通知公司其所持公司部分股份于近期被四川省安 岳县人民法院轮候冻结，具体情况如下： | 股东 | 是 | 否 | 为控 | 本 次 | 冻结 | 占 其 | 所 | 持 | 占公司 | 是否为 | 本 次 | 轮 | 本 | 次 | 冻 | 本 次 | 冻 | 结 | 冻结原因 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股 | 股 | 东及 | 股 份 | 数量 | 股份比例 | | | 总股本 | 限售股 | 候 冻 | 结 | 结 | 到 | 期 | 申请人 | | | | | | | 一 | 致 | 行动 | （股） | | | | | 比例 | | 起始日 | | 日 | | | | | | | | | | 人 ...

Group 1 - The core point of the news is that Huayu Pharmaceutical announced that shareholder Huang Qianyi's shares have been frozen by the Sichuan Anyue County People's Court, affecting a total of 1,300,000 shares recently [1] - As of December 10, 2025, a total of 7,650,738 shares held by Huang Qianyi have been frozen, which represents 28.11% of his holdings and 1.81% of the company's total share capital [1] - For the year 2024, Huayu Pharmaceutical's revenue composition is heavily weighted towards pharmaceuticals, accounting for 99.18%, while other businesses contribute only 0.82% [1] Group 2 - As of the latest report, Huayu Pharmaceutical has a market capitalization of 7.9 billion yuan [2]

Core Viewpoint - The announcement from Huiyu Pharmaceutical indicates that shareholder Huang Qianyi holds 27,219,439 shares, representing 6.43% of the total share capital, with a portion of his shares being frozen due to a debt contract dispute [1] Group 1 - Huang Qianyi's 1,300,000 shares have been temporarily frozen by the People's Court of Anyue County, Sichuan Province, due to a debt contract dispute [1] - As of December 10, 2025, a total of 7,650,738 shares have been frozen, which accounts for 28.11% of Huang Qianyi's holdings and 1.81% of the company's total share capital [1] - Huang Qianyi is neither a controlling shareholder nor the largest shareholder, and this matter does not affect the company's control or operations [1]

Core Viewpoint - The company will decide on potential share reductions based on development needs and the stock price fluctuations of Tongyuan Kang [1] Summary by Relevant Sections - Company Holdings: The company holds shares in Tongyuan Kang and will provide updates on its holdings in regular reports [1]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Policy Developments - The State Council, led by Li Qiang, held a meeting to advance the provincial coordination of basic medical insurance [2] Medical Device Approvals - Yuhanglong received two medical device registration certificates for diagnostic kits related to primary biliary cholangitis and idiopathic membranous nephropathy, enhancing its product line in liver and kidney disease diagnostics [4] - Hengrui Medicine announced the approval of clinical trial notifications for five drugs, including the humanized anti-PD-L1 monoclonal antibody Abedilizumab, with total R&D investments amounting to approximately 1.1 billion yuan [5] Capital Market Activities - Mindray Medical's chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan, having already purchased shares worth approximately 30 million yuan [7] - Huayu Pharmaceutical intends to establish a private equity fund focused on the biomedical sector, with an initial commitment of 150 million yuan from the company [8][9] Industry Milestones - The first brain-computer interface surgery in China was successfully completed, utilizing a device from Wuhan Zhonghua Brain-Machine Fusion Technology Co., with the procedure priced according to government regulations [11] Clinical Trials and Collaborations - Buchang Pharmaceutical's subsidiary signed a contract for clinical trials of a new product, with a total cost of approximately 60 million yuan, aimed at enhancing the company's drug development capabilities [12] - Jincheng Pharmaceutical terminated negotiations with Giskit Pharma B.V. regarding exclusive commercialization rights, with no financial impact expected [14]

Group 1 - Tianpu Co., Ltd. has experienced significant stock price volatility, with a cumulative increase of 451.80% from August 22, 2025, to November 27, 2025, leading to a suspension of trading for verification starting November 28, 2025 [1] Group 2 - FAW Jiefang plans to increase capital in its joint venture, Jiefang Times, by 191 million yuan, with a total capital increase of 412 million yuan alongside CATL and new investor Telepower, enhancing competitiveness in the new energy commercial vehicle sector [2] Group 3 - Qingdao Beer plans to invest in low-risk financial products with a maximum daily balance of 10 billion yuan over the next 12 months to improve fund efficiency and returns for shareholders [3] - Haohan Deep plans to acquire a 16.0656% stake in Guorui Smart for 70.68864 million yuan, increasing its ownership to 51.0656% [3] Group 4 - Huazhi Jie intends to invest 100 million yuan to establish Suzhou Kangyang Robot Co., Ltd., aligning with its strategic development plans [4] - Maide Medical's chairman proposes a share buyback of 20 million to 40 million yuan to reduce registered capital [4] Group 5 - Haichang New Materials plans to acquire 51% of Shenzhen Xinwei Communication Technology Co., Ltd. for 23.46 million yuan, gaining control over the company [5] - Hunan Gold's subsidiary obtained a mining license for a tungsten mine with an annual production capacity of 990,000 tons [5] Group 6 - Tianli Lithium Energy received two invention patents related to lithium-ion battery electrode materials, enhancing its core technology and competitive edge [6] Group 7 - Changan Automobile's indirect controlling shareholder underwent a restructuring, resulting in a new entity, China Changan Automobile Group, which holds 35.04% of Changan Automobile's shares [7] Group 8 - *ST Lian Shi's stock will resume trading on November 28, 2025, following a capital reserve increase [8] - Jia You International signed a strategic cooperation memorandum with the China-Africa Development Fund, expected to positively impact business development [8] Group 9 - China Aluminum International's subsidiary won a contract for a project worth 2.9086858 billion yuan, which could enhance the company's operational scale and profitability [9] Group 10 - Guizhou Sanli changed its stock abbreviation to "Sanli Pharmaceutical," while maintaining its full name and stock code [10] - China CRRC plans to spin off its subsidiary, CRRC Qichu, for listing on the Shenzhen Stock Exchange, retaining control over the subsidiary [10] Group 11 - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on integrated circuit-related sectors [11] - Huiyu Pharmaceutical intends to co-invest in a biomedical venture capital fund with a total initial subscription of 400 million yuan [11] Group 12 - Everbright Bank received notification of a shareholding increase by CITIC Financial Asset Management, raising its stake from 8.00% to 9.00% [12] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan within six months [12][13]

Core Viewpoint - The company, Huili Pharmaceutical, announced plans to jointly invest in a new private equity fund focused on the biomedical sector, particularly targeting late-stage clinical projects with clear commercial potential [1] Group 1: Investment Details - Huili Pharmaceutical will collaborate with Hangzhou Xiaochi Private Equity Fund Management Co., Ltd. to establish Chengdu Huili Xiaochi Biomedical Venture Capital Partnership (Limited Partnership) [1] - The initial subscription scale of the private equity fund is set at 400 million yuan, with Huili Pharmaceutical committing 150 million yuan, representing 37.5% of the total initial subscription amount [1]

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-092 四川汇宇制药股份有限公司 关于与专业机构合作投资设立私募基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的：成都汇宇晓池生物医疗创业投资合伙企业（有限合伙）（暂定 名，以企业登记机关最终核准的名称为准，以下简称"私募基金"或"合伙企业"）， 基金的投资领域为：主要投资于生物医疗领域，重点聚焦管线处于临床关键中后 期、具备明确商业潜力的投资标的。 投资金额：该私募基金目标募集资金规模为人民币 10 亿元整，初始认缴 规模为人民币 4 亿元整，四川汇宇制药股份公司（以下简称"公司"或"汇宇制 药"）拟作为有限合伙人以自有资金认缴出资人民币 1.5 亿元，将占该基金初始 认缴募资规模 37.50%（以下简称"本次投资"），投资期内根据基金投资要求实 缴到位。 本次对外投资事项不属于关联交易，亦不构成《上市公司重大资产重组 管理办法》、《科创板上市公司重大资产重组特别规定》规定的重大资产重组。 交易实施尚需履行的审批及其他相关程序 ...